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Pregnancy: A Review of the Literature
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Abstract
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids
and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists
(TPO-RAs), there has been a shift in treatment modalities. Eltrombopag and romiplostim have proven to be effective in
the management of ITP through clinical studies, but their safety in pregnancy remains uncertain. The purpose of the
study is to review the literature to evaluate the safety of TPO-RAs in pregnant women. Ten case reports and a cohort
study pertaining to the use of TPO-RAs in pregnancy were obtained. According to the reported cases and prospective
study, the use of eltrombopag and romiplostim appears to be relatively safe in the ﬁrst, second, and third trimesters, as
there were no reported congenital malformations. Low fetal birth weight has been observed following the administration of eltrombopag during the second trimester, whereas preterm birth has occurred following the administration of
eltrombopag in the third trimester. Eltrombopag and romiplostim seem relatively safe. Further studies are necessary to
clarify their safety during pregnancy.
Keywords: Eltrombopag, Newborn, Pregnancy, Romiplostim, Thrombopoietin mimetics, Thrombocytopenia

1. Introduction

I

mmune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low production
in platelets, which places an individual at risk of
bleeding [1]. The pathophysiology behind ITP involves an antibody-mediated destruction of platelets
through the glycoprotein IIa/IIIa receptor on platelet
cell surface that results in reduced platelet production [2e4]. A normal platelet level ranges between
150 and 450  109/L, whereas in patients with ITP,
the platelet count is usually below 100  109/L [1].
The management of ITP involves several lines of
therapy. First-line treatment options include corticosteroids or intravenous immunoglobulin (IVIG)

[5]. In patients with refractory or chronic ITP, second-line treatment options include different modalities such as splenectomy or the use of rituximab
[1,6]. With the emergence of novel therapies such as
thrombopoietin receptor agonists (TPO-RAs) that
include
avatrombopag,
eltrombopag,
lusutrombopag, and romiplostim, splenectomy rates
have fallen drastically, which shifted the placement
of splenectomy from a second-line to a third-line
treatment option [7]. According to the American
Society of Hematology (ASH) guideline, TPO-RAs
are given to patients diagnosed with ITP for
3 months who are either steroid-dependent or refractory to ﬁrst-line agents such as IVIG [8].
Eltrombopag is Food and Drug Administration
(FDA) approved for the treatment of aplastic anemia
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and ITP, avatrombopag is FDA approved for ITP
and thrombocytopenia associated with chronic liver
disease, lusutrombopag is only approved for
thrombocytopenia associated with chronic liver
disease, whereas romiplostim is only approved for
ITP [9e12]. TPO-RAs bind to and activate TPO receptors, which are found on the cell surface of
platelets. After their activation, intracellular signal
transduction transpires causing an elevation in
platelet count [13,14]. They proved to be effective in
the management of thrombocytopenia through
clinical studies [15e21].
Data regarding the safety of TPO-RAs in pregnancy are limited. Preclinical animal-based studies
conducted on female pregnant rats and rabbits have
observed low birth weight at higher doses of
eltrombopag, avatrombopag, and lusutrombopag,
whereas the administration of romiplostim led to
thrombocytosis and mortality in pups [9e12]. Our
objective is to evaluate the safety of TPO-RAs in
pregnant women through a review of the literature.

2. Methods
Articles pertaining to the use of eltrombopag and
romiplostim in pregnancy were retrieved through a
comprehensive literature search by using several
databases. Studies involving avatrombopag and
lusutrombopag were not available. The databases
used include PubMed, Scopus, Cochrane library,
and Web of Science. Search terms such as eltrombopag, romiplostim, pregnancy, thrombopoietin
receptor agonists, and thrombopoietin mimetics
were used during database search to target comparable articles. Only 10 case reports and one cohort
study were found and retrieved. Two case reports
described the use of eltrombopag and romiplostim
through the ﬁrst trimester, whereas two case reports
described the use of eltrombopag and one case
report described the use of romiplostim during the
second trimester. Two and three case reports
described the use of eltrombopag and romiplostim
during the third trimester, respectively. Regarding
the cohort study, the study was prospective and
assessed the use of TPO-RAs during all trimesters.

3. Results
3.1. Thrombopoietin receptor agonists use during
the ﬁrst trimester of pregnancy
3.1.1. Eltrombopag
The use of eltrombopag during the ﬁrst trimester
of pregnancy has been described in one case report,
which focused on a previously diagnosed 25-yearold female with ITP who was on maintenance

therapy with 8 mg/day prednisolone. While she was
on prednisolone, her platelet count was at 10  109/
L. The patient’s obstetric history included two
induced abortions because of the reduced level of
platelet count that was unsuccessfully controlled by
transfusion. After the administration of 12.5 mg/day
eltrombopag prior to pregnancy, her platelet count
remained above 50  109/L. Eltrombopag was
continued after conception and throughout the
pregnancy. During the pregnancy, the patient’s
platelet count remained at 60  109/L; however, it
dropped to 19  109/L at 36 weeks of gestation. She
was then diagnosed with gestational hypertension
(blood pressure, 150 mmHg) at 37 weeks of gestation. The patient gave birth to a low birth weight
baby (1670 g) with no congenital malformations. The
newborn, whose platelet count was 416  109/L,
remained in good health 1 month after delivery.
3.1.2. Romiplostim
An additional report described the use of romiplostim in a 28-year-old woman with a history of
refractory ITP. The patient was previously treated
with IVIG, prednisone, azathioprine, and rituximab.
Five months prior to conception, the patient was
initiated on romiplostim. During gestation, romiplostim was continued at a dose of 3 mg/kg/week.
Dexamethasone and IVIG were administered after
14 weeks of gestation because of a relapse episode
resulting in a platelet count of 7  109/L. Her platelet
count stabilized thereafter while the patient
remained on romiplostim. At 33 weeks of gestation,
induction of labor was initiated because of persistently severe incidents of thrombocytopenia experienced by the patient. During labor, the patient’s
platelet count was 200e300  109/L after the
administration of intravenous hydrocortisone at
50 mg every 6 hours. The patient gave birth to a
male newborn with a low birth weight of 1910 g and
a platelet count of 70  109/L. The neonate was born
with phimosis and suspected adrenal insufﬁciency.
The newborn’s platelet count was 186  109/L. Eight
hours after delivery, the neonate’s platelet count
dropped to 33  109/L, which prompted the administration of IVIG that stabilized his platelet count to
116  109/L. Ten months after delivery, the baby’s
health condition was normal.
3.2. Thrombopoietin receptor agonists use during
the second trimester of pregnancy
3.2.1. Eltrombopag
Two case reports described the use of eltrombopag during the second trimester of pregnancy. The
ﬁrst case report involved a 33-year-old female with a
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history of chronic idiopathic thrombocytopenic
purpura. At 25 weeks of gestation, she was hospitalized because of ITP relapse with severe decline in
platelet count reaching a level of 3  109/L. During
her admission, she was initiated on a glucocorticoid
that resulted in a substantial increase of platelet
count. One week later she was initiated on IVIG,
which had a similar effect to corticotherapy utilization (30  109/L). As the patient’s platelet count
remained below normal levels, further treatment
was warranted. Azathioprine was administered;
however, at 27 weeks of gestation the patient
developed hematuria. After treatment failure, the
patient was initiated on eltrombopag at a dose of
50 mg/day starting at 27 weeks of gestation. After
the administration of eltrombopag, the patient’s
platelet count increased to 70  109/L. Eltrombopag
dose was reduced to 25 mg/day after the patient was
discharged at 29 weeks of gestation. Because her
platelet count was further increased to a normal
level of 346  109/L during the 30th week, eltrombopag was discontinued. A female newborn with a
low birth weight of 2400 g was delivered. The
neonate presented with no bleeding and congenital
deformities.
The second case report focused on the use of
eltrombopag in a 27-year-old woman who was
previously diagnosed with ITP. Her obstetric history
included ﬁve pregnancies and three abortions. At
26 weeks of gestation, she was admitted because of a
relapse of ITP. Her platelet count was 10  109/L
despite being on 50 and 40 mg of azathioprine and
prednisolone, respectively. Because of her poor
response to prednisolone and azathioprine, the patient received platelet transfusions. After failing
several treatment options, the patient was started on
eltrombopag 25 mg daily and at 29 weeks of gestation. One week later, eltrombopag dose was titrated
to 50 mg/day. Her platelet count increased to
30  109/L. Her levels were maintained at 30  109/L
throughout the remainder of her pregnancy. She
had preterm labor at 36 weeks of gestation and gave
birth to a male newborn with low birth weight
(1860 g) and platelet count (145  109/L). At
discharge, the newborn’s platelet count was
249  109/L. Her platelet count after delivery was
55  109/L, which led to the discontinuation of
eltrombopag. At 6 weeks postpartum, the mother’s
platelet count stabilized at 70  109/L.
3.2.2. Romiplostim
A case of a 34-year-old female diagnosed with
immune thrombocytopenia at 17 weeks of gestation
was reported. Her platelet count upon admission
was 20  109/L. She was started on prednisone 1 mg/

3

kg/day, which was discontinued because of lack of
improvement in platelet counts (10  109/L) after
3 weeks of administration. IVIG, which was given at
a dose of 1 g/kg/day, showed comparable results to
prednisone on platelet count. Clinical and laboratory ﬁndings were indicative of poor prognosis; the
patient’s platelet count dropped signiﬁcantly to
4  109/L with signs and symptoms of gingival
bleeding and headache. As the patient was refractory to initial therapy with prednisone and IVIG,
romiplostim was initiated at 4 mg/kg/week. Her
platelet count signiﬁcantly improved to 110  109/L
5 days after administration. Treatment with romiplostim was continued throughout pregnancy with a
maintenance dose of 3 mg/kg/week. At 39 weeks of
gestation, she gave birth to 3480 g female newborn
with no evidence of malformation.
3.3. Thrombopoietin receptor agonists use during
the third trimester of pregnancy
3.3.1. Eltrombopag
The reported case involved a 41-year-old female
with an inherited form of thrombocytopenia mediated by a mutation in the MYH9 gene denoted as
p.Met1934TrpfsX14. The patient's obstetric history
included complicated labor because of uterine atony
that resulted in severe postpartum hemorrhage with
subsequent hemoglobin (Hgb) level of 6.5 g/dL. Her
platelet count through her ﬁrst pregnancy was
26  109/L. During her second pregnancy, eltrombopag was initiated after 36 weeks of gestation at
50 mg/day. The patient was considered eligible
because of her previous complicated delivery and
platelet count of 26  109/L obtained prior to labor.
The safety of eltrombopag was evaluated by
assessing thrombopoietin levels as well as any
evident physical ﬁnding. In terms of efﬁcacy,
19 days after the administration of eltrombopag, the
patient's platelet count peaked at 179  109/L
compared to her platelet level of 30  109/L prior to
eltrombopag administration, whereas the safety
proﬁle during treatment remained insigniﬁcant.
Eltrombopag was discontinued on Day 24 as a result
of premature labor that required a cesarean section.
The patient successfully gave birth without
requiring transfusion; however, her Hgb level was
10.2 g/dL postpartum. The newborn weighed 3145 g
with no congenital deformity. The baby inherited
the MYH9 genetic mutation and had a platelet count
of 62  109/L.
Another report described a case of a 24-year-old
female with ITP, for which she was diagnosed during her ﬁrst pregnancy. Her platelet count was
9  109/L. She is gravida 3, para 2 + 0. She was
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initiated on IVIG and dexamethasone. After a suboptimal response to IVIG and corticotherapy, she
was given eltrombopag during her last trimester for
which her platelet count has stabilized. During her
third pregnancy, the patient was admitted for preterm labor. She had a relapse episode of ITP with
platelet count 41  109/L and Hgb 10.2 g/dL. She
was given 50 mg/day of eltrombopag, 40 mg of
dexamethasone, and transfusion during the third
trimester. She gave birth to a newborn with severe
thrombocytopenia. Six weeks postpartum, she
experienced vaginal bleeding. She received IVIG for
2 days, dexamethasone for 14 days, and rituximab.
Eltrombopag dose was titrated to 75 mg/day.
3.3.2. Romiplostim
A 34-year-old female with a platelet count of
55  109/L and clinical ﬁndings of epistaxis and
bruising at 8 weeks of gestation was diagnosed with
ITP 2 years ago. At 12 weeks’ gestation, her platelet
count was 36  109/L; she was therefore initiated on
prednisone (1 mg/kg/day). Four weeks after the
administration of prednisone, the patient’s platelet
count remained at 36  109/L. IVIG (1 g/kg) was
administered, resulting in an increase in platelet
count of 50  109/L. At 28 weeks of gestation, romiplostim was given at 4 mg/kg/week because of the
decreased platelet count (26  109/L) after 3 months
of IVIG administration. On Day 15 after initiation
with romiplostim, her platelet count increased to
100  109/L. Her platelet count was maintained between 50 and 100  109/L with romiplostim maintenance dose of 3 mg/kg/week. At 38 weeks of
gestation, she gave birth to a 2640 g female newborn
without any congenital malformation. The newborn’s platelet count was 90  109/L but returned to
normal levels 5 days after delivery.
An additional report described a case of a 34-yearold female who is gravida 6 para 5. She was
admitted because of petechiae, hematuria, epistaxis,
and gingival bleeding. Her platelet count was
3  109/L, which conﬁrmed a diagnosis of ITP. She
was given IVIG 2 g/kg with 20 mg of IV dexamethasone. After treatment with IVIG and dexamethasone, the patient’s platelet count remained between
2 and 5  109/L. Further treatment options were
given because of platelet count instability that
included: rituximab 375 mg/m2/week, pulsed
500 mg cyclophosphamide, and 50 mg of eltrombopag with dose titration of 75 mg/day. Because the
patient was near term, romiplostim 3 mg/kg/week
was given to accelerate platelet response prior to
labor. Six days after the administration of romiplostim, her platelet count was 65  109/L, which
further increased to 91  109/L a week later. Owing

to ﬂuctuations in platelet response, induction of
labor was implemented at 34 weeks of gestation.
During labor, her platelet count was 52  109/L. She
gave birth to a healthy female newborn with normal
platelet level.
Another 34-year-old female was admitted at
29 weeks of gestation (twin pregnancy) because of
hematuria, petechiae, mucosal blisters, and a
platelet count of 1  109/L, which conﬁrmed the
diagnosis of ITP. She was given 1 mg/kg prednisolone and 0.4 g/kg IVIG for 5 days. Her platelet count
increased to 12  109/L. Her platelet count reached
7  109/L 10 days after discharge. Her platelet count
further declined to 1  109/L and IVIG was administered. Anti-D immunoglobulin 250 IU/kg was
given; however, her platelet count decreased to
3  109/L. Owing to the lack of response to anti-D,
azathioprine was given at 50 mg/day and was
titrated to 100 mg/day. At 32 weeks of gestation,
optimizing the platelet count became necessary
because the patient was reaching term. Romiplostim
(2 mg/kg) as a single dose was given. No further
doses of romiplostim were administered. The patient’s condition did not improve, leading to seven
plasma exchanges. Further doses of 1 g/kg of IVIG
were administered. Her platelet count then rose to
37  109/L. During labor, her platelet count was
79  109/L. She gave birth to twins with a platelet
count of 20  109/L who were both treated with
0.4 g/kg IVIG for 5 days.
3.4. Prospective studies
A prospective cohort study assessed the safety
and efﬁcacy of both romiplostim and eltrombopag
in 15 pregnant women with chronic ITP who had 17
pregnancies (with one twin pregnancy) and 18 neonates. Eight pregnant women received eltrombopag with doses of 25e100 mg/day. Eltrombopag was
initiated during the ﬁrst trimester and continued for
9e12 weeks in three pregnancies, whereas ﬁve
pregnant women received eltrombopag during the
third trimester and continued till delivery. Pregnant
women on eltrombopag had received two to seven
treatment-lines prior to eltrombopag administration, including splenectomy in three women. Prior
to eltrombopag initiation, the platelet count was
2e15  109/L; however, the platelet count at the time
of delivery was 23e169  109/L. Four neonates
whose mothers were on eltrombopag developed
neonatal thrombocytopenia (6e34  109/L) and two
had different events: neonatal thrombocytosis
(555  109/L) and intracranial hemorrhage.
Moreover, seven women received romiplostim
during pregnancy with doses of 3e10 mg/kg.
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Romiplostim was initiated during the third trimester
for all pregnancies (31e39 weeks) and continued for
1e6 weeks. Pregnant women had received two to
seven treatment-lines prior to romiplostim administration including splenectomy in three women.
The platelet count prior to romiplostim administration was 1e20  109/L, by contrast, the platelet
count during delivery was 6e250  109/L. Two neonates developed neonatal thrombocytopenia
(4  109/L and 20  109/L) whereas one neonate had
pulmonary artery stenosis. One neonate had trisomy 8 and died on Day 7 after delivery.

4. Discussion
Our review highlights the use of TPO-RAs in pregnant women to further identify their safety proﬁle. The
use of TPO-RAs in pregnancy has been deemed
challenging because of the lack of information pertaining to their utilization. The case reports and cohort
study present the administration of eltrombopag and
romiplostim during pregnancy while considering the
risks and beneﬁts. All case reports have mentioned the
use of eltrombopag and romiplostim in patients who
were refractory to ﬁrst-line treatment options such as
IVIG, corticotherapy, azathioprine, cyclophosphamide, rituximab, and transfusion.
Animal studies pertaining to the use of TPO-RAs
in pregnancy were reported. Regarding eltrombopag, doses of 10, 20, and 60 mg/kg/day were
administered to female rats during the embryonic
stage. At higher doses, low fetal birth weight was
observed in addition to implantation loss. High dose
eltrombopag in rats resulted in 6e7% decrease in
fetal weight. In an embryo developmental study on
rabbits, serum plasma levels of eltrombopag was
detected in the fetus after administering 30, 80, and
150 mg/kg/day. The doses administered did not lead
to fetotoxicity or teratogenicity. Several animal
studies pertaining to romiplostim were reported.
Romiplostim was found to cross the placenta in
pups, which led to loss of implantation, thrombocytosis, and mortality. Moreover, doses that were 11
and 82 times higher were administered to female
rats and rabbits, respectively. This increase in the
recommended dose administered in humans has
not caused any fetal harm [9,12].
According to the FDA, counseling pregnant
women regarding the potential harmful effects of
eltrombopag during pregnancy is essential. The
FDA recommends appropriate contraception (by
utilizing contraceptive methods that would result
in < 1% pregnancy rates) with the use of eltrombopag during pregnancy and for 7 days after the last
dose. Regarding romiplostim, the FDA urges
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pregnant women to apply to the pregnancy registry.
The administration of eltrombopag or romiplostim
in pregnant women should only be implemented if
the beneﬁts outweigh the risks as stated by the FDA
[9,12]. A common approach mentioned in the case
reports was the utilization of several treatment options such as glucocorticoid therapy (prednisolone,
prednisone, or dexamethasone), azathioprine, IVIG,
rituximab, cyclophosphamide, anti-D, and platelet
transfusion prior to initiating a TPO-RA. The case
reports highlighted the use of eltrombopag and
romiplostim as a last line of therapy after obtaining
consent from patients.
The approved dosage of romiplostim starts at 1 mg/
kg/week, with titration of up to 10 mg/kg/week
depending on platelet levels. The approved eltrombopag dosage starts at 50 mg/day, with titration
down to 25 mg/kg or up to 75 mg/kg based on
platelet response [9]. In the case reports, during the
ﬁrst trimester, romiplostim dosage was 3 mg/kg/
week, whereas that of eltrombopag was 12.5 mg/day.
During the second trimester, the doses of eltrombopag administered ranged between 25 and 50 mg/
day, whereas romiplostim was administered at 4 mg/
kg/week. During the third trimester, eltrombopag
dosage ranged between 50 and 75 mg/day and that
of romiplostim ranged from 2 to 4 mg/kg/week.
According to the reported cases and prospective
study, use of eltrombopag and romiplostim appears
to be relatively safe in the ﬁrst trimester, as there
were no reported congenital malformations. However, in one case report, the newborn’s weight was
1670 g with the administration of eltrombopag,
which is considered low [22]. Both case reports
demonstrated insigniﬁcant outcomes in terms of
maternal health. Moreover, use of eltrombopag
during the second trimester resulted in abnormal
fetal weight. In both case reports pertaining to
eltrombopag, the fetal weight was 2400 and 1860 g.
As for romiplostim, the fetal weight was 3480, which
is considered above the normal fetal weight of
2500 g [22]. In addition, the administration of
eltrombopag and romiplostim during the second
trimester did not result in congenital malformations.
The administration of eltrombopag and romiplostim
during the third trimester has been demonstrated
through the prospective study and several case reports. In both case reports pertaining to eltrombopag, both pregnancies have been preterm and the
fetal birth weight was not affected. Meanwhile,
romiplostim administration during the third
trimester did not show signiﬁcant fetal/maternal
outcomes.
Our review has several limitations. Data regarding
the use of eltrombopag and romiplostim in

6

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:1e6

pregnancy are limited. There were no clinical trials
demonstrating the safety of both medications in
pregnancy, which led to the retrieval of case reports
and a prospective study for the review. Moreover,
certain case reports did not mention the outcome on
maternal and fetal health.

5. Conclusion
The administration of eltrombopag and romiplostim during all trimesters of pregnancy seems relatively safe. However, there seems to be an association
between the administration of eltrombopag during
the ﬁrst/second trimester and low fetal birth weight.
This ﬁnding may seem confounded by the administration of other drug classes such as rituximab, IVIG,
azathioprine, or corticotherapy. Further studies
showcasing the safety of eltrombopag and romiplostim during pregnancy are necessary to classify
TPO-RAs as either safe or harmful during pregnancy.
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